The data from the first few days at ASCO is real. The conclusions being drawn from it are doing considerably more work than the evidence supports. Ivonescimab beat a PD-1 inhibitor on OS in China. Grail showed stage shift across 140,000 NHS patients. MRD posted its strongest conference presence to date. Each of those results is worth taking seriously.
8 min read
ASCO
Milestone Monday: A Win in China. A Shift in England. A Gap Nobody Named.
Three ASCO readouts, three announcements that claimed more than the data supported — and one question the conference floor has been too busy to ask.
